In Segment A, participants will get different doses and schedules of oral ABBV-744 tablet to recognize safe dosing routine. Additional individuals will likely be enrolled within the identified monotherapy dosign regimen. In Section B, members will get oral ruxolitinib and ABBV-744 will probably be provided as "insert-on" therapy. In Phase https://abbv-744-clinical-trial-p35689.ltfblog.com/31078797/5-simple-statements-about-abbv-744-clinical-trial-phase-1-results-explained